Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

Market Cap	33.28B
Revenue (ttm)	511.35M
Net Income (ttm)	-878.57M
Shares Out	459.41M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,190,876
Average Volume	2,936,176
Open	71.77
Previous Close	71.02
Day's Range	70.88 - 73.50
52-Week Range	37.58 - 86.18
Beta	0.20
RSI	46.83
Earnings Date	Oct 29, 2025

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 852
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688192

Financial Performance

In 2024, SHA:688192's revenue was 359.90 million, an increase of 294.24% compared to the previous year's 91.29 million. Losses were -845.96 million, -23.63% less than in 2023.